BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/16/2024 6:29:25 AM | Browse: 42 | Download: 115
 |
Received |
|
2024-08-01 15:06 |
|
Peer-Review Started |
|
2024-08-01 15:06 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-09-07 15:07 |
|
Revised |
|
2024-09-15 03:23 |
|
Second Decision |
|
2024-09-23 02:37 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-09-23 06:10 |
|
Articles in Press |
|
2024-09-23 06:10 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2024-09-27 01:57 |
|
Typeset the Manuscript |
|
2024-09-30 04:52 |
|
Publish the Manuscript Online |
|
2024-10-16 06:29 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hang Zhang, Xuan Dong, Lei Zhu and Fu-Shan Tang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fu-Shan Tang, PhD, Professor, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, No. 6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com |
| Key Words |
Elafibranor; Peroxisome proliferator activated receptor; Liver fibrosis; Alcoholic liver disease; Metabolic-associated fatty liver disease; Metabolic-associated steatohepatitis; Cholestatic liver disease; Primary biliary cholangitis; Liver diseases |
| Core Tip |
This article provides a critical evaluation of the study by Koizumi et al on the effects of Elafibranor on liver fibrosis and gut barrier function in a mouse model of alcoholic liver disease (ALD). It reviews recent advancements in the use of Elafibranor for treating ALD, metabolic-associated fatty liver disease, and cholestatic liver disease, and explores its therapeutic potential. Additionally, it outlines future prospects for Elafibranor’s application. The aim is to promote broader use of Elafibranor in managing these liver conditions and to highlight its potential role in advancing clinical treatments. |
| Publish Date |
2024-10-16 06:29 |
| Citation |
<p>Zhang H, Dong X, Zhu L, Tang FS. Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease. <i>World J Gastroenterol</i> 2024; 39(40): 4393-4398</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i40/4393.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i40.4393 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
